We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 28, 2022

CNS Efficacy of Furmonertinib vs Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study
J Thorac Oncol 2022 Aug 03;[EPub Ahead of Print], Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao, C Liu, S Zhu, X Zhang, Y Li, J Liu, L Cao, Y Cheng, H Zhao, S Zhang, A Zang, J Cui, J Feng, N Yang, F Liu, Y Jiang, C Gu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading